GENE ONLINE|News &
Opinion
Blog

2022-07-22| Special

Shifting From Counterculture to Clinical Applications, The Problems Psychedelics Face Getting to Market

by Reed Slater
Share To

The clinical application of psychedelics like MDMA, psilocybin, and LSD is gaining support daily. The class of drugs is quickly shedding its stigma as more research demonstrates the promise of treating ever-pervasive mental health disorders like depression, anxiety, and bipolar. Even with a growing acceptance, psychedelic therapies face significant challenges before they have a chance at making it to the market. 

At BIO International Convention in San Diego, five esteemed professionals in the field discussed the hurdles clinical psychedelic development faces before it can benefit the millions of people in need of better mental health treatments. The panel highlighted problems like scalability, clinical limitations, intellectual property issues, and overcoming the stigma of psychedelics.

GO Prime with only $1.49 now

LATEST
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Moderna Welcomes Phase 3 Win For RSV Vaccine
2023-01-18
Moving Beyond COVID With mRNA Technology
2023-01-18
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
2023-01-17
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
2023-01-16
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
2023-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!